Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Phase 1/2 Study of PRO1160 in Patients with Metastatic Renal Cell Carcinoma (RCC), Metastatic or Relapsed Nasopharyngeal Carcinoma (NPC), or Advanced (Stage III or IV) Non-Hodgkin Lymphoma (NHL)

    Cancer Categories
    • Genitourinary (GU),Hematologic (Blood Cancers),Lung
    Karmanos Trial ID
    • 2023-018
    NCT ID
    • NCT05721222
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator


    Primary Objectives:

    • Evaluate the safety and tolerability of PRO1160
    • Identify the maximum tolerated dose (MTD), if reached, and the recommended Phase 2 dose (RP2D) of PRO1160

    Secondary Objectives:

    • Assess the antitumor activity of PRO1160
    • Assess the pharmacokinetics (PK) of PRO1160
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266